Sarcomatoid
Challenges and limitation of MTAP immunohistochemistry in diagnosing desmoplastic mesothelioma/sarcomatoid pleural mesothelioma with desmoplastic features
Annals of Diagnostic Pathology 2022 June 30 [Link] Prakasit Sa-Ngiamwibool, Makoto Hamasaki, Yoshiaki Kinoshita, Shinji Matsumoto, Ayuko Sato, Tohru Tsujimura, Takahiko Kasai, Kenzo Hiroshima, Kei Kushitani, Yukio Takeshima, Kunimitsu Kawahara, Akinori Iwasaki, Kazuki Nabeshima Abstract Aim: Genomic-based ancillary assays including immunohistochemistry (IHC) for BRCA-1 associated protein-1 (BAP1) and methylthioadenosine phosphorylase (MTAP), and fluorescence in situ…
Read MorePrognostic factors of malignant peritoneal mesothelioma: a retrospective study of 52 female patients
World Journal of Surgical Oncology 2022 June 29 [Link]Jianting Ma, Shengzhi Zhang Abstract Background: Prognosis in malignant peritoneal mesothelioma (MPM) remains poor, and the associated factors are unclear. Therefore, this study aimed to investigate the prognostic factors of MPM. Methods: A total of 52 female MPM patients treated in 2012-2017 were retrospectively analyzed. Kaplan-Meier survival…
Read MoreGenomics of Tumor Origin and Characteristics for Adenocarcinoma and Malignant Pleural Mesothelioma: A Case Report
Frontiers in Oncology 2022 May 19 [Link] Katsuo Usuda, Yo Niida, Masahito Ishikawa, Shun Iwai, Aika Yamagata, Yoshihito Iijima, Nozomu Motono, Sohsuke Yamada, Hidetaka Uramoto Abstract A female underwent a right middle lobectomy for a pulmonary adenocarcinoma (AD). She eventually died of a right malignant pleural mesothelioma (MPM; sarcomatoid type) 4 years and 7 months…
Read MoreBAP1 and Claudin-4, But Not MTAP, Reliably Distinguish Borderline and Low-grade Serous Ovarian Tumors From Peritoneal Mesothelioma
International Journal of Gynecological Pathology 2022 March 29 [Link] Kyle M Devins, Lawrence Zukerberg, Jaclyn C Watkins, Yin Pun Hung, Esther Oliva Abstract Peritoneal mesothelioma (PM) and serous neoplasms can be difficult to differentiate, particularly in small biopsies. BRCA1-associated protein 1 (BAP1) is expressed in benign tissues, but over 50% of PMs demonstrate complete loss…
Read MoreDissecting and Reconstructing Matrix in Malignant Mesothelioma Through Histocell-Histochemistry Gradients for Clinical Applications
Frontiers in Medicine 2022 April 13 [Link] Marcelo Luiz Balancin, Camila Machado Baldavira, Tabatha Gutierrez Prieto, Juliana Machado-Rugolo, Cecília Farhat, Aline Kawassaki Assato, Ana Paula Pereira Velosa, Walcy Rosolia Teodoro, Alexandre Muxfeldt Ab’Saber, Teresa Yae Takagaki, Vera Luiza Capelozzi Abstract Background: Malignant pleural mesotheliomas (MM) are known for their heterogenous histology and clinical behavior. MM…
Read MoreExpression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study
The Journal of Surgical Research 2022 April 27 [Link] Victor P Gazivoda, Aaron W Kangas-Dick, Alissa A Greenbaum, Joshua Roshal, Chunxia Chen, Dirk F Moore, Russell C Langan, Timothy J Kennedy, Christine Minerowicz, H Richard Alexander Abstract Introduction: Frequency of PD-L1 expression and the role of immunotherapy in malignant peritoneal mesothelioma (MPM) have not been…
Read MoreMicro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma and mediate epithelial to mesenchymal transition
Virchows Archiv 2022 April 24 [Link] Francesca Napoli, Ida Rapa, Stefania Izzo, Angelica Rigutto, Roberta Libener, Chiara Riganti, Paolo Bironzo, Riccardo Taulli, Mauro Papotti, Marco Volante, Giorgio Scagliotti, Luisella Righi Abstract The standard front-line treatment for pleural mesothelioma (PM) is pemetrexed-based chemotherapy, whose major target is thymidylate synthase (TS). In several cancer models, miR-215 and…
Read MorePrognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients
Lung Cancer 2022 March 19 [Link] Ludovic Fournel, Thomas Charrier, Maxime Huriet, Amedeo Iaffaldano, Audrey Lupo, Diane Damotte, Jennifer Arrondeau, Marco Alifano Abstract Background: Prediction of prognosis is a key step of malignant pleural mesothelioma (MPM) management and treatment assignment. Aim of this study was to identify simple prognostic factors, focusing on inflammation-related parameters. Methods:…
Read MoreUsefulness of Cyclin D1/Podoplanin Dual Immunohistochemical Stain to Differentiate Malignant Mesothelioma From Reactive Mesothelial Proliferations
American Journal of Clinical Pathology 2022 March 14 [Link] Raghavendra Pillappa, Austin Wiles, Sadia Sayeed, Valentina Robila Abstract Objectives: To examine the potential of cyclin D1/podoplanin dual immunohistochemical stain to differentiate malignant mesothelioma from reactive mesothelial proliferations. Methods: Cyclin D1/podoplanin dual immunohistochemistry was performed on 34 surgical cases of reactive mesothelial proliferations, malignant mesothelioma, and…
Read MoreSarcopenia, Precardial Adipose Tissue and High Tumor Volume as Outcome Predictors in Surgically Treated Pleural Mesothelioma
Diagnostics (Basel) 2022 January 3 [Link] Oliver Guido Verhoek, Lisa Jungblut, Olivia Lauk, Christian Blüthgen, Isabelle Opitz, Thomas Frauenfelder, Katharina Martini Abstract Background: We evaluated the prognostic value of Sarcopenia, low precardial adipose-tissue (PAT), and high tumor-volume in the outcome of surgically-treated pleural mesothelioma (PM). Methods: From 2005 to 2020, consecutive surgically-treated PM-patients having a…
Read More